Benzbromarone, quercetin, and folic acid inhibit amylin aggregation

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  López, Laura C ^a   Varea, Olga ^a   Navarro, Susanna ^b   Carrodeguas, José A ^a   De Groot, Natalia Sanchez ^b   Ventura, Salvador ^b   Sancho, Javier ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Aggregation; Amylin; Amyloid; Benzbromarone; Folic acid; Quercetin; Type II diabetes

Indexed keywords

AMYLIN; BENZBROMARONE; FOLIC ACID; QUERCETIN; THIOFLAVINE; AMYLOID;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; HELA CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; INSULIN DEFICIENCY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PROTEIN AGGREGATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; TURBIDIMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; PROTEINOSIS;

AMYLOID; ANIMALS; BENZBROMARONE; FOLIC ACID; HELA CELLS; HUMANS; ISLET AMYLOID POLYPEPTIDE; PROTEIN AGGREGATION, PATHOLOGICAL; QUERCETIN; RATS;

EID: 84975140907     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060964     Document Type: Article

References (58)

1. Danaei, G.; Finucane, M.M.; Lu, Y.; Singh, G.M.; Cowan, M.J.; Paciorek, C.J.; Lin, J.K.; Farzadfar, F.; Khang, Y.H.; Stevens, G.A. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378, 31–40. [CrossRef]
2. National Diabetes Statistics Report, 2014. Available online: http://www.cdc.gov/diabetes/pubs/ statsreport14/national-diabetes-report-web.pdf (accessed on 15 June 2016).
3. Marzban, L.; Park, K.; Verchere, C.B. Islet amyloid polypeptide and type 2 diabetes. Exp. Gerontol. 2003, 38, 347–351. [CrossRef]
4. Kumar, V.; Tausto, N.; Abbas, A. Robbins and Cotran Pathologic Basis of Disease, 7th ed.; Saunders: Philadelphia, PA, USA, 2005.
5. Hayden, M.R. Pancreatic islet amyloid in type 2 diabetes mellitus: A clinical and historical review. Mol. Med. 2002, 99, 495–498.
6. Westermark, P.; Wilander, E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978, 15, 417–421. [CrossRef][PubMed]
7. Mirzabekov, T.A.; Lin, M.C.; Kagan, B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 1996, 271, 1988–1992. [PubMed]
8. Westermark, P.; Wernstedt, C.; Wilander, E.; Hayden, D.W.; O’Brien, T.D.; Johnson, K.H. Amyloid fibrils in human insulinoma and islets of langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA 1987, 84, 3881–3885. [CrossRef][PubMed]
9. Westermark, P.; Engstrom, U.; Johnson, K.H.; Westermark, G.T.; Betsholtz, C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 1990, 87, 5036–5040. [CrossRef][PubMed]
10. Moriarty, D.F.; Raleigh, D.P. Effects of sequential proline substitutions on amyloid formation by human amylin 20–29. Biochemistry 1999, 38, 1811–1818. [CrossRef][PubMed]
11. Kelly, J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 1998, 8, 101–106. [CrossRef]
12. Luca, S.; Yau, W.M.; Leapman, R.; Tycko, R. Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR. Biochemistry 2007, 46, 13505–13522. [CrossRef][PubMed]
13. Serpell, L.C.; Sunde, M.; Benson, M.D.; Tennent, G.A.; Pepys, M.B.; Fraser, P.E. The protofilament substructure of amyloid fibrils. J. Mol. Biol. 2000, 300, 1033–1039. [CrossRef][PubMed]
14. Sunde, M.; Blake, C.C. From the globular to the fibrous state: Protein structure and structural conversion in amyloid formation. Q. Rev. Biophys. 1998, 31, 1–39. [CrossRef][PubMed]
15. Anguiano, M.; Nowak, R.J.; Lansbury, P.T., Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type ii diabetes. Biochemistry 2002, 41, 11338–11343. [CrossRef][PubMed]
16. Haataja, L.; Gurlo, T.; Huang, C.J.; Butler, P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 2008, 29, 303–316. [CrossRef][PubMed]
17. Janson, J.; Ashley, R.H.; Harrison, D.; McIntyre, S.; Butler, P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48, 491–498. [CrossRef][PubMed]
18. Konarkowska, B.; Aitken, J.F.; Kistler, J.; Zhang, S.; Cooper, G.J. The aggregation potential of human amylin determines its cytotoxicity towards islet ˜-cells. FEBS J. 2006, 273, 3614–3624. [CrossRef][PubMed]
19. Lin, C.Y.; Gurlo, T.; Kayed, R.; Butler, A.E.; Haataja, L.; Glabe, C.G.; Butler, P.C. Toxic human islet amyloid polypeptide (H-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-iapp-induced ˜-cell apoptosis in H-IAPP transgenic mice. Diabetes 2007, 56, 1324–1332. [CrossRef][PubMed]
20. Ritter, C.; Maddelein, M.L.; Siemer, A.B.; Luhrs, T.; Ernst, M.; Meier, B.H.; Saupe, S.J.; Riek, R. Correlation of structural elements and infectivity of the HET-S prion. Nature 2005, 435, 844–848. [CrossRef][PubMed]
21. Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid _ oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 2007, 282, 10311–10324. [CrossRef][PubMed]
22. Glenner, G.G.; Wong, C.W. Alzheimer’s disease and down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122, 1131–1135. [CrossRef]
23. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Flanagan, L.; de Silva, H.A.; Kittel, A.; Saitoh, T. The precursor protein of non-A˜ component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14, 467–475. [CrossRef]
24. McLaurin, J.; Kierstead, M.E.; Brown, M.E.; Hawkes, C.A.; Lambermon, M.H.; Phinney, A.L.; Darabie, A.A.; Cousins, J.E.; French, J.E.; Lan, M.F. et al. Cyclohexanehexol inhibitors of A˜ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12, 801–808. [CrossRef][PubMed]
25. Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.; Perez, K. et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A˜. Neuron 2008, 59, 43–55. [CrossRef][PubMed]
26. Ma, K.; Thomason, L.A.; McLaurin, J. Scyllo-inositol, preclinical, and clinical data for Alzheimer’s disease. Adv. Pharmacol. 2012, 64, 177–212. [PubMed]
27. Wischik, C.M.; Staff, R.T.; Wischik, D.J.; Bentham, P.; Murray, A.D.; Storey, J.M.; Kook, K.A.; Harrington, C.R. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer’s disease. J. Alzheimer’s Dis. 2015, 44, 705–720.
28. Abian, O.; Vega, S.; Sancho, J.; Velazquez-Campoy, A. Allosteric inhibitors of the NS3 protease from the hepatitis c virus. PLoS ONE 2013, 8, e69773. [CrossRef][PubMed]
29. Conesa, C.; Doss, M.X.; Antzelevitch, C.; Sachinidis, A.; Sancho, J.; Carrodeguas, J.A. Identification of specific pluripotent stem cell death—Inducing small molecules by chemical screening. Stem Cell Rev. 2012, 8, 116–127. [CrossRef][PubMed]
30. Cremades, N.; Velazquez-Campoy, A.; Martinez-Julvez, M.; Neira, J.L.; Perez-Dorado, I.; Hermoso, J.; Jimenez, P.; Lanas, A.; Hoffman, P.S.; Sancho, J. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against helicobacter pylori infection. ACS Chem. Biol. 2009, 4, 928–938. [CrossRef][PubMed]
31. Lopez, L.C.; Dos-Reis, S.; Espargaro, A.; Carrodeguas, J.A.; Maddelein, M.L.; Ventura, S.; Sancho, J. Discovery of novel inhibitors of amyloid ˜-peptide 1-42 aggregation. J. Med. Chem. 2012, 55, 9521–9530. [CrossRef][PubMed]
32. Pey, A.L.; Ying, M.; Cremades, N.; Velazquez-Campoy, A.; Scherer, T.; Thony, B.; Sancho, J.; Martinez, A. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Investig. 2008, 118, 2858–2867. [CrossRef][PubMed]
33. Sanchez de Groot, N.; Pallares, I.; Aviles, F.X.; Vendrell, J.; Ventura, S. Prediction of “hot spots” of aggregation in disease-linked polypeptides. BMC Struct. Biol. 2005, 5, 18. [CrossRef][PubMed]
34. Jaikaran, E.T.; Higham, C.E.; Serpell, L.C.; Zurdo, J.; Gross, M.; Clark, A.; Fraser, P.E. Identification of a novel human islet amyloid polypeptide ˜-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 2001, 308, 515–525. [CrossRef][PubMed]
35. LeVine, H., 3rd. Thioflavine t interaction with synthetic Alzheimer’s disease _-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 1993, 2, 404–410. [CrossRef][PubMed]
36. Lorenzo, A.; Yankner, B.A. B-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 1994, 91, 12243–12247. [CrossRef][PubMed]
37. Trikha, S.; Jeremic, A.M. Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasma membrane cholesterol. J. Biol. Chem. 2011, 286, 36086–36097. [CrossRef][PubMed]
38. Kumar, S.; Ng, J.; Gow, P. Benzbromarone therapy in management of refractory gout. N. Z. Med. J. 2005, 118, U1528. [PubMed]
39. Cai, H.Y.; Wang, T.; Zhao, J.C.; Sun, P.; Yan, G.R.; Ding, H.P.; Li, Y.X.; Wang, H.Y.; Zhu, W.L.; Chen, K.X. Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice. Acta Pharmacol. Sin. 2013, 34, 1397–1402. [CrossRef][PubMed]
40. Sudchada, P.; Saokaew, S.; Sridetch, S.; Incampa, S.; Jaiyen, S.; Khaithong, W. Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2012, 98, 151–158. [CrossRef][PubMed]
41. Mangoni, A.A.; Sherwood, R.A.; Asonganyi, B.; Swift, C.G.; Thomas, S.; Jackson, S.H. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am. J. Hypertens. 2005, 18, 220–226. [CrossRef][PubMed]
42. Aguirre, L.; Arias, N.; Macarulla, M.T.; Gracia, A.; Portillo, M.P. Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J. 2011, 4, 189–198.
43. Bardy, G.; Virsolvy, A.; Quignard, J.F.; Ravier, M.A.; Bertrand, G.; Dalle, S.; Cros, G.; Magous, R.; Richard, S.; Oiry, C. Quercetin induces insulin secretion by direct activation of l-type calcium channels in pancreatic ˜ cells. Br. J. Pharmacol. 2013, 169, 1102–1113. [CrossRef][PubMed]
44. Coskun, O.; Kanter, M.; Korkmaz, A.; Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and ˜-cell damage in rat pancreas. Pharmacol. Res. 2005, 51, 117–123. [CrossRef][PubMed]
45. Kim, J.H.; Kang, M.J.; Choi, H.N.; Jeong, S.M.; Lee, Y.M.; Kim, J.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract. 2011, 5, 107–111. [CrossRef][PubMed]
46. Mahesh, T.; Menon, V.P. Quercetin allievates oxidative stress in streptozotocin-induced diabetic rats. Phytother. Res. 2004, 18, 123–127. [CrossRef][PubMed]
47. Vessal, M.; Hemmati, M.; Vasei, M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp. Biochem. Physiol. Toxicol. Pharmacol. 2003, 135C, 357–364. [CrossRef]
48. Adewole, S.O.; Caxton-Martins, E.A.; Ojewole, J.A. Protective effect of quercetin on the morphology of pancreatic ˜-cells of streptozotocin-treated diabetic rats. Afr. J. Tradit. Complement. Altern. Med. 2006, 4, 64–74. [CrossRef][PubMed]
49. Ramachandra, R.; Shetty, A.K.; Salimath, P.V. Quercetin alleviates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats. Mol. Nutr. Food Res. 2005, 49, 355–360. [CrossRef][PubMed]
50. Jeong, S.M.; Kang, M.J.; Choi, H.N.; Kim, J.H.; Kim, J.I. Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr. Res. Pract. 2012, 6, 201–207. [CrossRef][PubMed]
51. ClinicalTrials.gov. Available online: http://clinicaltrials.gov/show/NCT01839344 (accessed on 31 May 2016).
52. Noor, H.; Cao, P.; Raleigh, D.P. Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid fibers. Protein Sci. 2012, 21, 373–382. [CrossRef][PubMed]
53. Zelus, C.; Fox, A.; Calciano, A.; Faridian, B.S.; Nogaj, L.A.; Moffet, D.A. Myricetin inhibits islet amyloid polypeptide (IAPP) aggregation and rescues living mammalian cells from iapp toxicity. Open Biochem. J. 2012, 6, 66–70. [CrossRef][PubMed]
54. Sato, M.; Murakami, K.; Uno, M.; Nakagawa, Y.; Katayama, S.; Akagi, K.; Masuda, Y.; Takegoshi, K.; Irie, K. Site-specific inhibitory mechanism for amyloid ˜42 aggregation by catechol-type flavonoids targeting the lys residues. J. Biol. Chem. 2013, 288, 23212–23224. [CrossRef][PubMed]
55. Gazova, Z.; Siposova, K.; Kurin, E.; Mucaji, P.; Nagy, M. Amyloid aggregation of lysozyme: The synergy study of red wine polyphenols. Proteins 2013, 81, 994–1004. [CrossRef][PubMed]
56. Wang, J.B.; Wang, Y.M.; Zeng, C.M. Quercetin inhibits amyloid fibrillation of bovine insulin and destabilizes preformed fibrils. Biochem. Biophys. Res. Commun. 2011, 415, 675–679. [CrossRef][PubMed]
57. Zhu, M.; Han, S.; Fink, A.L. Oxidized quercetin inhibits —-synuclein fibrillization. Biochim. Biophys. Acta 2013, 1830, 2872–2881. [CrossRef][PubMed]
58. Di Giovanni, S.; Eleuteri, S.; Paleologou, K.E.; Yin, G.; Zweckstetter, M.; Carrupt, P.A.; Lashuel, H.A. Entacapone and tolcapone, two catechol o-methyltransferase inhibitors, block fibril formation of —-synuclein and ˜-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem. 2010, 285, 14941–14954. [CrossRef][PubMed]